Company / Capital Expenditures
BeOne Medicines Ltd. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$185.8M
FY2025
5-year range
$185.8M / $561.9M
FY2021-FY2025
Trend
-62.3%
vs FY2024
Sector context
#17 of 194
Health Care
What the data says
Among 194 Health Care companies, BeOne Medicines Ltd. is in the top 9% for capital expenditures. Declined from $562M to $186M over the past 2 years.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of +9.6%. Top quartile in the Health Care sector.
Declined from $562M to $186M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -17.0%
- 5-Year CAGR
- +9.6%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 194This company $185.8M Sector average $117.5M
▼
+58.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.6%, indicating consistent growth.
- In FY2025, capital expenditures decreased 62.3% year-over-year.
- Ranks #17 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $185.8M | -62.3% |
| FY2024 | $492.7M | -12.3% |
| FY2023 | $561.9M | +72.7% |
| FY2022 | $325.4M | +23.8% |
| FY2021 | $262.9M | +123.8% |
| FY2020 | $117.5M | +31.1% |
| FY2019 | $89.6M | +27.5% |
| FY2018 | $70.3M | +51.6% |
| FY2017 | $46.4M | +97.3% |
| FY2016 | $23.5M | +342.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026